Dexcom Showcases Breakthrough Outcomes for People With Type 2 Diabetes and Product Roadmap at ATTD 2026 [Yahoo! Finance]
DexCom, Inc. (DXCM)
Last dexcom, inc. earnings: 4/28 04:03 pm
Check Earnings Report
US:NASDAQ Investor Relations:
dexcom.com/investors
Company Research
Source: Yahoo! Finance
New registry study data shows that long-term use of Dexcom G7 supports weight management and lowers A1C for people with Type 2 diabetes who aren't on insulin therapy reinforcing the need to broaden CGM access beyond insulin-treated populations. During its symposium on Thursday, March 12, Dexcom will share upcoming product features across its global portfolio. Two in-booth, expert-led presentations on Thursday, March 12, and Friday, March 13 will showcase the first consensus-based CGM competency framework to give healthcare professionals a clear, role-aligned structure for delivering confident, consistent CGM support. BARCELONA, Spain, March 11, 2026 BUSINESS WIRE DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, will present new findings that showcase the benefits of its glucose biosensing technology for people with all types of diabetes and share more details about future product features across its global portfolio at the upcoming 19 th annual Advanced Tech
Show less
Read more
Impact Snapshot
Event Time:
DXCM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DXCM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DXCM alerts
High impacting DexCom, Inc. news events
Weekly update
A roundup of the hottest topics
DXCM
News
- We tried continuous glucose monitors from Lingo and Stelo for 2 weeks. Here's which one is better [CNN]CNN
- DexCom (DXCM) had its price target raised by Citigroup Inc. from $77.00 to $84.00. They now have a "buy" rating on the stock.MarketBeat
- Dexcom Showcases Breakthrough Outcomes for People With Type 2 Diabetes and Product Roadmap at ATTD 2026Business Wire
- DexCom (DXCM) had its "buy" rating reaffirmed by BTIG Research. They now have a $85.00 price target on the stock.MarketBeat
- DexCom (DXCM) was upgraded by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from "sell (d+)" to "hold (c-)".MarketBeat
DXCM
Earnings
- 2/12/26 - Beat
DXCM
Sec Filings
- 3/10/26 - Form 4
- 3/10/26 - Form 4
- 3/10/26 - Form 4
- DXCM's page on the SEC website